Company: BLNE
Filing Date: 2025-03-27
Form Type: 424B7
Source: 0001641172-25-000822
Chunk: 11

Company: Beeline Holdings, Inc.
Filing Date: 2025-03-27
Form: 424B7
Chunk 11
---
 Registration Rights Agreement and side letter agreement do not purport to be complete and are qualified in their entirety by the full text of such agreements, which are included as exhibits to the Company’s filings with the SEC and are incorporated herein by reference.

| S-13 |

<div align='center'>RISK FACTORS</div>

Any investment in our securities involves a high degree of risk. Investors should carefully consider the risks described below and all of the information contained in this prospectus before deciding whether to purchase our securities. Our business, financial condition and results of operations could be materially adversely affected by these risks if any of them actually occur. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face as described below and elsewhere in this prospectus.

Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our Final Prospectus filed under Rule 424(b)(3) on January 14, 2025, our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we have filed or will file with the SEC, which are incorporated by reference into this prospectus.

Our business, affairs, prospects, assets, financial condition, results of operations and cash flows could be materially and adversely affected by these risks. For more information about our SEC filings, please see “Where You Can Find More Information”.

Risks Related to the Purchase Agreement with C/M

The sale or issuance of our common stock to C/M will create dilution to our other shareholders and the sale of the shares of common stock acquired by C/M, or the perception that such sales may occur, could cause the price of our common stock to fall.

| S-14 |

Pursuant to the Purchase Agreement with C/M C/M has committed to purchase up to $10,000,000 of our common stock, of which this prospectus supplement relates to $3,500,000 and prior prospectus supplements filed on March 10, 2025 and March 26, 2025 relates to an additional $4,000,000 (for a combined total of $7,500,000 of common stock among such prospectus supplements). The shares of common stock that may be sold pursuant to the Purchase Agreement may be sold by